Table 2.

Best overall response*

Characteristic	Immunocompromised
	No (n = 35), (Proportion [95% Confidence Interval])	Yes (n = 18), (Proportion [95% Confidence Interval])	Total (n = 53), (Proportion [95% Confidence Interval])
Best response as per hierarchical response assessment#
Complete response	11 (35% [19, 55])	4 (27% [8, 55])	15 (33% [20, 48])
Partial response	8 (26% [12, 45])	3 (20% [4, 48])	11 (24% [13, 39])
Stable disease	6 (19% [7, 37])	6 (40% [16, 68])	12 (26% [14, 41])
Progressive disease	6 (19% [7, 37])	2 (13% [2, 40])	8 (17% [8, 31])
Missing	4	3	7
Best RECIST 1.1 response
Complete response	5 (42% [15, 72])	0	5 (33% [12, 62])
Partial response	0	1 (33% [1, 91])	1 (7% [0, 32])
Stable disease	4 (33% [10, 65])	2 (67% [9, 99])	6 (40% [16, 68])
Progressive disease	3 (25% [5, 57])	0	3 (20% [4, 48])
Best WHO clinical response
Complete response	0	1 (100% [3, 100])	1 (33% [1, 91])
Stable disease	2 (100% [16, 100])	0	2 (67% [9, 99])
Best PERCIST 1.0 response
Complete metabolic response	7 (30% [13, 53])	3 (27% [6, 61])	10 (29% [15, 47])
Partial metabolic response	8 (35% [16, 57])	2 (18% [2, 52])	10 (29% [15, 47])
Stable metabolic disease	2 (9% [1, 28])	4 (36% [11, 69])	6 (18% [7, 35])
Progressive metabolic disease	6 (26% [10, 48])	2 (18% [2, 52])	8 (24% [11, 41])

FDG-PET fluorodeoxyglucose positron emission tomography, PERCIST1.0 Positron Emission Tomography Response Criteria, RECIST1.1 Response Evaluation Criteria in Solid Tumors, WHO World Health Organization

^*Seven patients were not evaluable (either due to death/cessation prior to first imaging assessment or non-measurable disease)

^#If more than one response criteria was utilised, then best response was determined based on RECIST1.1. If no RECIST1.1 response was available, WHO clinical response criteria were used. If no WHO response was available, PERCIST1.0 on FDG-PET was used